Detection of lung adenocarcinoma using magnetic beads based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling

Chinese Medical Journal

Volumn 123, Issue 1, 2010, Pages 34-39

  Lin, Xiu Li ^a   Yang, Shuan Ying ^a   Du, Jie ^a   Tian, Ying Xuan ^a   Bu, Li Na ^a   Huo, Shu Fen ^a   Wang, Feng Peng ^a   Nan, Yan Dong ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Lung adenocarcinoma; Magnetic beads; Matrix assisted laser desorption ionization mass spectrometry; Proteomics; Serum

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; COMPLEMENT COMPONENT C3; GUANINE NUCLEOTIDE BINDING PROTEIN; PLASMA PROTEIN; POLYPEPTIDE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CATION EXCHANGE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; EUKARYOTE; FEMALE; GENETIC ALGORITHM; HUMAN; LUNG ADENOCARCINOMA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ISOLATION; PROTEIN PURIFICATION; SENSITIVITY AND SPECIFICITY; SERUM; TECHNOLOGY;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETICS; MALE; MICROSPHERES; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 74749107746     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.01.006     Document Type: Article

References (20)

1. Yang DC, Yang SY. The current status and progress of lung cancer diagnosis. Chin J Tuberc Respir Dis (Chin) 2004; 27: 18-19.
2. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004; 76: 1560-1570.
3. Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC, et al. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and post-treatment head and neck cancer samples. Laryngoscope 2008; 118: 61-68.
4. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116: 271-284.
5. de Noo ME, Mertens BJ, Ozalp A, Bladergroen MR, van der Werff MP, van de Velde CJ, et al. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur J Cancer 2006; 42: 1068-1076.
6. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P. A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol Cell Proteomics 2008; 7: 509-518.
7. Ebert MP, Niemeyer D, Deininger SO, Wex T, Knippig C, Hoffmann J, et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res 2006; 5: 2152-2158.
8. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005; 51: 2236-2244.
9. Chang JT, Chen LC, Wei SY, Chen YJ, Wang HM, Liao CT, et al. Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry-plasma peptidomes from nasopharyngeal cancer patients for example. Clin Biochem 2006; 39: 1144-1151.
10. Bosso N, Chinello C, Picozzi SCM, Gianazza E, Mainini V, Galbusera C, et al. Human urine biomarkers of renal cell carcinoma evaluated by ClinProt. Proteomics Clin Appl 2008; 2: 1036-1046.
11. Kojima K, Asmellash S, Klug CA, Grizzle WE, Mobley JA, Christein JD. Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer. J Gastrointest Surg 2008; 12: 1683-1690.
12. Leung SM, Mok SC. Quality management of ovarian cancer serum profiles using functionalized magnetic beads, AnchorChip (TM) technology, MALDI-TOF MS and, MALDI-TOF/TOF MS. AACR Annual Meeting; 2004: 1205.
13. Leung SM, Sheldon M, Lau CC. A novel and rapid approach to protein expression profiling of cerebrospinal fluid (CSF) from medulloblastoma patients using functionalized magnetic beads, AnchorChip(TM) technology, MALDI-TOF and MALDI-TOF/TOF mass spectrometry. Neuro-Oncology 2004; 6: 410-410.
14. Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, et al. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics 2005; 4: 1341-1349.
15. West-Norager M, Kelstrup CD, Schou C, Hogdall EV, Hogdall CK, Heegaard NH. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 847: 30-37.
16. Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005; 5: 83.
17. Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, et al. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 2008; 31: 133-139.
18. Luo XY, Chen HQ, Wang WJ, Liao P, Xiang CQ. The study of lung adenocarcinoma serum biomarkers selected by surface-enhanced laser desorption ionization spectrometry. Chin Oncol 2006; 16: 14-16.
19. Merkulova TI, Frolova LY, Lazar M, Camonis J, Kisselev LL. C-terminal domains of human translation termination factors eRF1 and eRF3 mediate their in vivo interaction. FEBS Lett 1999; 443: 41-47.
20. Chai B, Wang W, Liang A. Nuclear localization of eukaryotic class II release factor (eRF3): Implication for the multifunction of eRF3 in ciliates Euplotes cell. Cell Biol Int 2008; 32: 353-357